MicroRNAs as Novel Biomarkers for Breast Cancer

H M Heneghan, N Miller, A J Lowery, K J Sweeney, M J Kerin, H M Heneghan, N Miller, A J Lowery, K J Sweeney, M J Kerin

Abstract

Breast cancer is a complex phenotypically diverse genetic disease, involving a variety of changes in gene expression and structure. Recent advances in molecular profiling technology have made great progress in unravelling the molecular taxonomy of breast cancer, which has shed new light on the aetiology of the disease and also heralded great potential for the development of novel biomarkers and therapeutic targets. Mi(cro)RNAs are a contemporary class of small noncoding endogenous RNA molecules, generating great excitement in the clinical and scientific communities. The recent discovery that miRNA expression is frequently dysregulated in cancer has uncovered an entirely new repertoire of molecular factors upstream of gene expression, which warrants extensive investigation to further elucidate their precise role in malignancy. We present a comprehensive and timely review of the role of miRNAs in cancer: addressing miRNA function, their putative role as oncogenes or tumor suppressors, with a particular emphasis on breast cancer throughout. We discuss the recent discovery of quantifiable circulating cancer-associated miRNAs, which heralds immense potential for their use as novel minimally invasive biomarkers for breast and other cancers. Finally, we comment on the potential role of miRNAs in breast cancer management, particularly in improving current prognostic tools and achieving the goal of individualized cancer treatment.

Figures

Figure 1
Figure 1
MiRNA biogenesis and processing in human cells: the multistep process begins in the nucleus where the RNase III enzyme Drosha, coupled with its binding partner DGCR8, cleaves nascent miRNA transcripts (pri-miRNA) into ~70 nucleotide precursors (pre-miRNA). These pre-miRNAs consist of an imperfect stem-loop structure. Pre-miRNAs are then exported from the nucleus into the cytoplasm by Exportin 5. In the cytoplasm, the hairpin precursors are cleaved by Dicer and its binding partner the transactivator RNA-binding protein TRBP into a small, imperfect dsRNA duplex (miRNA : miRNA*) that contains both the mature miRNA strand and its complementary strand. The miRNA strand is incorporated into the miRNP complex and targets complementary mRNA sequences, exerting its functionality via mRNA cleavage or translational repression.

References

    1. Garcia M, et al. Global Cancer Facts & Figures 2007. Atlanta, Ga, USA: American Cancer Society; 2007.
    1. National Cancer Registry Ireland, Cancer projections 2005–2035, 2008.
    1. Jackson RJ, Standart N. How do microRNA's regulate gene expression? Science's STKE. 2007;367(1)
    1. Lowery AJ, Miller N, McNeill RE, Kerin MJ. MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clinical Cancer Research. 2008;14(2):360–365.
    1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297.
    1. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.
    1. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Research. 2008;36(supplement 1):D154–D158.
    1. Berezikov E, Guryev V, van de Belt J. Phylogenetic shadowing and computational identification of human microRNA genes. Cell. 2005;120(1):21–24.
    1. Castoldi M, Schmidt S, Benes V, et al. A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA) RNA. 2006;12(5):913–920.
    1. Abbott AL, Alvarez-Saavedra E, Miska EA, et al. The let-7 MicroRNA family members mir-48, mir-84, and mir-241 function together to regulate developmental timing in Caenorhabditis elegans . Developmental Cell. 2005;9(3):403–414.
    1. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–838.
    1. Lao K, Xu NL, Yeung V, Chen C, Livak KJ, Straus NA. Multiplexing RT-PCR for the detection of multiple miRNA species in small samples. Biochemical and Biophysical Research Communications. 2006;343(1):85–89.
    1. Hutvágner G, Simard MJ, Mello CC, Zamore PD. Sequence-specific inhibition of small RNA function. PLoS Biology. 2004;2(4, article e98)
    1. Meister G, Landthaler M, Dorsett Y, Tuschl T. Sequence-specific inhibition of microRNA-and siRNA-induced RNA silencing. RNA. 2004;10(3):544–550.
    1. Boutla A, Delidakis C, Tabler M. Developmental defects by antisense-mediated inactivation of micro-RNAs 2 and 13 in Drosophila and the identification of putative target genes. Nucleic Acids Research. 2003;31(17):4973–4980.
    1. Ørom UA, Kauppinen S, Lund AH. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene. 2006;372(1-2):137–141.
    1. Si M-L, Zhu S, Wu H, Lu Z, Wu F, Mo Y-Y. miR-21-mediated tumor growth. Oncogene. 2007;26(19):2799–2803.
    1. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438(7068):685–689.
    1. Gentner B, Schira G, Giustacchini A, et al. Stable knockdown of microRNA in vivo by lentiviral vectors. Nature Methods. 2009;6(1):63–66.
    1. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell. 2008;133(2):217–222.
    1. Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Research. 2007;67(16):7713–7722.
    1. Medina PP, Slack FJ. Inhibiting microRNA function in vivo. Nature Methods. 2009;6(1):37–38.
    1. Franco-Zorrilla JM, Valli A, Todesco M, et al. Target mimicry provides a new mechanism for regulation of microRNA activity. Nature Genetics. 2007;39(8):1033–1037.
    1. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(24):15524–15529.
    1. Volinia S, Calin GA, Liu C-G, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(7):2257–2261.
    1. Iorio MV, Ferracin M, Liu C-G, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Research. 2005;65(16):7065–7070.
    1. Mattie MD, Benz CC, Bowers J, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Molecular Cancer. 2006;5, article 24
    1. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Research. 2007;67(18):8699–8707.
    1. Dahiya N, Sherman-Baust CA, Wang T-L, et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One. 2008;3(6, article e2436)
    1. Wu W, Lin Z, Zhuang Z, Liang X. Expression profile of mammalian MicroRNAS in endometrioid adenocarcinoma. European Journal of Cancer Prevention. 2009;18(1):50–55.
    1. Chung TKH, Cheung T-H, Huen N-Y, et al. Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. International Journal of Cancer. 2009;124(6):1358–1365.
    1. Boren T, Xiong Y, Hakam A, et al. MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecologic Oncology. 2008;110(2):206–215.
    1. Perou CM, Sørile T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752.
    1. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America. 2001;98(19):10869–10874.
    1. Sørlie T, Wang Y. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006;7, article 127
    1. Van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–536.
    1. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. The New England Journal of Medicine. 2009;360(8):790–800.
    1. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. The New England Journal of Medicine. 2004;351(27):2817–2826.
    1. Negrini M, Rasio D, Hampton GM, et al. Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. Cancer Research. 1995;55(14):3003–3007.
    1. Makiyama K, Hamada J, Takada M, et al. Aberrant expression of HOX genes in human invasive breast carcinoma. Oncology Reports. 2005;13(4):673–679.
    1. Lowery AJ, et al. Micro-RNA expression profiling in primary breast tumours. European Journal of Cancer. 2007;5(supplement 3)
    1. Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N. Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Molecular Biology. 2008;9, article 76
    1. McNeill RE, Miller N, Kerin MJ. Evaluation and validation of candidate endogenous control genes for real-time quantitative PCR studies of breast cancer. BMC Molecular Biology. 2007;8, article 107
    1. Taplin S, Abraham L, Barlow WE, et al. Mammography facility characteristics associated with interpretive accuracy of screening mammography. Journal of the National Cancer Institute. 2008;100(12):876–887.
    1. Thompson A, Brennan K, Cox A, et al. Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Research. 2008;10(2, article R26)
    1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. The New England Journal of Medicine. 2005;353(16):1659–1672.
    1. Harris L, Fritsche H, Mennel R, et al. American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology. 2007;25(33):5287–5312.
    1. O'Hanlon DM, Kerin MJ, Kent P, Maher D, Grimes H, Given HF. An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma. British Journal of Cancer. 1995;71(6):1288–1291.
    1. Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, Fukutomi T. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. International Journal of Clinical Oncology. 2008;13(5):447–451.
    1. Xi Y, Nakajima G, Gavin E, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA. 2007;13(10):1668–1674.
    1. Li J, Smyth P, Flavin R, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnology. 2007;7, article 36
    1. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. British Journal of Haematology. 2008;141(5):672–675.
    1. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(30):10513–10518.
    1. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Research. 2008;18(10):997–1006.
    1. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS One. 2008;3(9, article e3148)
    1. Chin LJ, Slack FJ. A truth serum for cancer—microRNAs have major potential as cancer biomarkers. Cell Research. 2008;18(10):983–984.
    1. Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell. 2006;9(6):435–443.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel